Risk Stratified Randomized Phase III Testing of Blinatumomab in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

About this Study

The study is being done to test whether the incorporation of blinatumomab into the treatment of patients with childhood B-Lymphoblastic Leukemia at first relapse will improve disease free survival. 

Sponsor Protocol ID:AALL1331
IRB Number:2015-0013
Actively Enrolling
Interventional
Phase 3
May 28, 2019
Eligibility Criteria
1 year old
31 years old
Both Male and Female
Yes
Yes
No

Inclusion CriteriaPatients ≥1 year of age

Exclusion Criteria
  • Patients with Burkitt Leukemia/Lymphoma or mature B-cell leukemia are not eligible.
  • Patients with known optic nerve and/or retinal involvement are not eligible.
  • Patients who are presenting with visual disturbances should
    have an ophthalmologic exam and, if indicated, an MRI to determine optic nerve or retinal involvement. 
  • Patients known to have one of the following concomitant genetic
    syndromes: Down syndrome, Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome.  Patients with known HIV infection. 
  •  Patients with known allergy to mitoxantrone, cytarabine, or both
    etoposide and etoposide phosphate (Etopophos).  
  • Lactating females who plan to breastfeed.

 

Categories Click category to view its trials.
Cancer
Pediatrics
Participating Locations
Children's of Mississippi Center for Cancer and Blood Disorders
Children’s of Mississippi Hospital - Blair E. Batson Tower
Contact Information
Contact Name: Maggie Goad
Phone Number: 601-984-2700
Email: mgoad@umc.edu
Principal Investigator:Betty H Melton
How to participate in our Clinical Trials